Latest Convertible Notes News

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

Innovaero Technologies is seeking A$40 million through a proposed ASX listing to advance its OWL loitering munition program and expand manufacturing capacity. The replacement prospectus also makes clear that the company remains loss-making and heavily dependent on the Department of Defence converting development work into production orders.

Ionic Rare Earths is pushing toward commercial magnet recycling in Belfast and the United States, but its FY2026 report flags a material uncertainty over its ability to continue as a going concern. The company reported a larger A$14.9 million loss and A$13.9 million in operating cash outflows, despite government support and new strategic partnerships.

New Hope delivered more coal, expanded its resource base and declared a 30-cent final dividend, but lower realised prices and higher costs cut FY26 profit by 63.4%. The results leave investors weighing near-term earnings pressure against a larger production pipeline.

Terramin Australia has launched a partially underwritten $28.65 million entitlement offer to fund project development and reduce debt owed to major shareholder Asipac. The raise could also materially reshape the company’s ownership, while its prospectus flags a material uncertainty over its ability to continue as a going concern.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

WasteCo is asking eligible New Zealand shareholders for up to NZ$750,000 in fresh equity as it tackles NZ$40.1 million of debt, a FY2026 loss and an aggressive operational reset. The non-underwritten plan follows a separate placement and is priced at NZ$0.007 per share.

Neometals has cleared a key regulatory hurdle for an A$2 million standby loan from a company controlled by former chairman David Reed. The facility provides near-term funding, but carries 10% interest, security over Barrambie-related assets and potential conversion into equity.

Neurizon will redeem 1 million convertible notes held by Obsidian for US$1.15 million, while securing a two-month standstill on share sales. The biotechnology company says the transaction leaves it funded through the HEALEY ALS trial readout and completion.

NEXTDC is seeking A$1.1 billion from institutional investors through subordinated convertible notes, adding to its funding capacity for an increasingly capital-intensive data centre pipeline. The deal offers a low indicative coupon, but introduces future dilution risk and could create short-term share price pressure through associated hedging activity.